MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Meridian Bioscience Total Current Liabilities 2011-2026 | VIVO
Annual Total Current Liabilities Meridian Bioscience
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 58 M | 47.2 M | 52.5 M | 20.9 M | 24.2 M | 22.9 M | 22.6 M | 15.3 M | 13.7 M | 21.7 M | 18.5 M | 15.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 58 M | 13.7 M | 27.7 M |
Total Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
169 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Bioventus
BVS
|
160 M | $ 8.9 | 0.39 % | $ 593 M |  USA |
 |
Castle Biosciences
CSTL
|
49.4 M | $ 26.04 | 0.81 % | $ 723 M | USA |
 |
Aspira Women's Health
AWH
|
5.78 M | - | -6.19 % | $ 10.5 M | USA |
 |
DexCom
DXCM
|
2.14 B | $ 68.33 | 2.99 % | $ 26.7 B | USA |
 |
Guardant Health
GH
|
303 M | $ 87.63 | 0.52 % | $ 11 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
13.8 M | - | - | $ 562 M |  Britain |
 |
Charles River Laboratories International
CRL
|
1.12 B | $ 154.73 | 1.82 % | $ 7.67 B | USA |
 |
CareDx, Inc
CDNA
|
89.8 M | $ 17.59 | 1.56 % | $ 937 M | USA |
 |
Accelerate Diagnostics
AXDX
|
66.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
IQVIA Holdings
IQV
|
8.34 B | $ 168.86 | 2.41 % | $ 29 B | USA |
 |
Exact Sciences Corporation
EXAS
|
641 M | $ 103.89 | 0.04 % | $ 19.6 B | USA |
 |
Global Cord Blood Corporation
CO
|
647 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
54.2 M | - | 1.08 % | $ 308 M | USA |
 |
Fulgent Genetics
FLGT
|
72.9 M | $ 15.62 | 4.45 % | $ 472 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.27 B | - | - | $ 10.7 B | USA |
|
Biodesix
BDSX
|
14.3 M | $ 16.88 | -2.37 % | $ 2.19 B | USA |
 |
ICON Public Limited Company
ICLR
|
2.8 B | $ 100.35 | 2.81 % | $ 8.28 B |  Irlanda |
 |
Anixa Biosciences
ANIX
|
1.97 M | $ 2.9 | 2.11 % | $ 94.1 K | USA |
 |
Danaher Corporation
DHR
|
6.81 B | $ 195.77 | 2.29 % | $ 140 B | USA |
 |
NeoGenomics
NEO
|
88.3 M | $ 8.36 | 1.46 % | $ 1.07 B | USA |
 |
Biocept
BIOC
|
5.51 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
39.6 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
8.27 M | - | -20.0 % | $ 1.06 M | USA |
 |
Pacific Biosciences of California
PACB
|
72.8 M | $ 1.4 | 2.95 % | $ 420 M | USA |
 |
Illumina
ILMN
|
1.55 B | $ 121.89 | 2.18 % | $ 19.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
2.28 B | $ 198.82 | -0.06 % | $ 22.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
544 M | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
1.71 B | $ 113.9 | 1.85 % | $ 34.6 B | USA |
 |
BioNano Genomics
BNGO
|
37.3 M | $ 1.12 | 0.9 % | $ 1.42 M | USA |
 |
DarioHealth Corp.
DRIO
|
12.5 M | $ 9.28 | 10.24 % | $ 263 M |  Israel |
 |
Neogen Corporation
NEOG
|
174 M | $ 9.32 | 2.25 % | $ 2.02 B | USA |
 |
Lantheus Holdings
LNTH
|
333 M | $ 78.96 | 0.59 % | $ 5.33 B | USA |
 |
Chembio Diagnostics
CEMI
|
39.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
1.81 M | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
5.75 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
1.34 B | $ 452.34 | -0.29 % | $ 13 B | USA |
 |
Motus GI Holdings
MOTS
|
3.27 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
1.2 B | $ 1 219.76 | 1.76 % | $ 25.1 B |  Schweiz |
 |
Celcuity
CELC
|
31.7 M | $ 114.23 | -0.58 % | $ 4.51 B | USA |
 |
DermTech
DMTK
|
13.4 M | - | -11.32 % | $ 2.94 M | USA |
 |
Twist Bioscience Corporation
TWST
|
91.4 M | $ 46.61 | 3.55 % | $ 2.79 B | USA |
 |
National Research Corporation
NRC
|
36.6 M | $ 18.05 | 3.71 % | $ 404 M | USA |
 |
Invitae Corporation
NVTA
|
108 M | - | - | $ 21.2 M | USA |
 |
Enzo Biochem
ENZ
|
24.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
310 M | $ 199.84 | 1.09 % | $ 19.7 B | USA |